Daniel Patience has worked at Biogen’s Chemical Process Development group for the past 5 years. Prior to that he has worked 10 years at GlaxoSmithKline, 4 years at Teva Pharmaceuticals (formerly Cephalon) and 1 year at Pfizer (formerly Pharmacia). All these roles have been in drug substance & drug product development groups working on small molecules and some biologics covering a range of activities including crystallization process design, process safety, flow chemistry, reaction engineering, upstream processing and formulation stability. Daniel received his Ph.D. in Chemical Engineering and M.S. in Food Science from the University of Wisconsin and his B.E. in Chemical Engineering from the University of Canterbury, New Zealand. He has authored, co-authored and presented 21 publications, presentations and patents.